Where to Buy Bioglutide (NA-931): 2026 Status

If you're searching for where to buy bioglutide, here's the honest status: it isn't in our vetted vendor lineup yet. Bioglutide — the research name for NA-931, an oral quadruple agonist — is an investigational compound still in clinical development and not FDA-approved. Early gray-market listings are starting to appear as it gets attention, but we don't yet track a source we've vetted for COA and identity.

This page tells you exactly where NA-931 sits in the pipeline, how to get notified the moment a vetted supply path opens, and what covers the same mechanisms today.

Research-context information only. Bioglutide (NA-931) is an investigational drug not approved by the FDA. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.

Current Status: Coming Soon

Bioglutide (NA-931) is an investigational compound in active clinical development. It is being run through human trials as an oral quadruple agonist — a single molecule reported to activate four pathways at once: IGF-1, GLP-1, GIP, and glucagon. That places it a mechanism ahead of the triple agonist retatrutide on paper.

The furthest-along public data point is the Phase 2 study, registered as NCT06564753 and presented at the American Diabetes Association's 2025 Scientific Sessions as late-breaking abstract 2189-LB. That readout reported 13.8% weight loss with the oral compound in study subjects. Earlier first-in-human work was published in Endocrine Practice. Both are trial-stage results — there is no FDA-approved product and no confirmed commercial launch date.

Here's what that means if you're looking to source it right now:

• It's oral, not injectable. The trial program tested NA-931 as an oral compound — no vial, no reconstitution, no bacteriostatic water. A listing selling "bioglutide" as a lyophilized injectable powder is describing something that doesn't match the trial compound.
• It's not in our vetted lineup yet. As a compound in active development, it hasn't entered the mainstream research-peptide catalogs we track. Early listings are beginning to surface, and vendors sometimes carry new compounds under code names — so we're watching availability closely and running it through discovery.
• Verify before you order. Until we can point you to a COA-tested source we trust, treat any current listing as unverified — confirm the identity and a batch COA before buying anything marketed as bioglutide or NA-931.

The bottom line: what's documented today is a Phase 2 obesity compound with strong early data. The moment a source we've vetted for COA and identity carries it, we'll say so — sign up below and you'll be first to know.

Get Notified When Bioglutide Launches

When a source we've vetted for COA and identity carries bioglutide, this is the fastest way to hear — before you have to weigh an unverified listing yourself.

No spam, no product to buy today — just a single alert if and when the availability status genuinely changes. Until then, the closest mechanism-overlap analog is covered below, with the caveats on how it compares.

What's Accessible Today: Retatrutide

The closest accessible analog to bioglutide right now is retatrutide — though it, too, is investigational, not FDA-approved, and sold for research purposes only. It is an injectable triple agonist (GLP-1, GIP, glucagon) that covers three of the four pathways NA-931 is reported to target — everything except the IGF-1 arm. Unlike bioglutide, retatrutide is widely stocked by research-peptide vendors today and can be compared on price and COA verification.

The trade-offs are worth stating plainly. Retatrutide is a subcutaneous injectable, not an oral compound, so the convenience angle that makes bioglutide interesting doesn't carry over. It is a mechanism overlap, not a clinical substitute for NA-931's own trial data. But on mechanism coverage and real-world availability, it is the nearest thing on the market by mechanism. The retatrutide dosing guide documents the trial-reported weight-loss data and community protocols in full, including its Phase 3 TRIUMPH results.

The vendor links below are affiliate links; The Peptide Catalog may earn a commission on purchases.

Affiliate disclosure: The Peptide Catalog earns a commission on purchases made through vendor links below.

Like bioglutide, retatrutide and cagrilintide are investigational compounds not approved by the FDA; tirzepatide is the active ingredient in FDA-approved products, but the research-peptide form is not. All are sold for research purposes only.

To compare current COA-verified retatrutide vendors, pricing, and active discount codes, see the retatrutide best page. Cagrilintide (an amylin analog) and tirzepatide (a GLP-1/GIP dual agonist) are the other widely stocked obesity-class peptides research buyers commonly compare alongside it.

What to Watch Next

1. A Phase 3 announcement. Until NA-931 advances further in human trials and toward a regulatory filing, "bioglutide" stays a trial-stage molecule with no legitimate consumer supply. The Phase 2 readout (NCT06564753 / ADA 2025 abstract 2189-LB) is the current high-water mark.
2. The oral-agonist race. An oral compound reporting 13.8% weight loss in Phase 2 is notable precisely because most high-efficacy obesity agents are injectable. Whether that oral advantage survives later-stage trials is the open question.
3. Verified availability only. The moment a genuinely verified supply path exists, the launch alert above is where it will surface. Until then, treat every "buy bioglutide now" listing as unverified.